CA2487811A1 - Use of adenoviruses replicating in a yb-1 dependent manner for the treatment of tumors - Google Patents
Use of adenoviruses replicating in a yb-1 dependent manner for the treatment of tumors Download PDFInfo
- Publication number
- CA2487811A1 CA2487811A1 CA002487811A CA2487811A CA2487811A1 CA 2487811 A1 CA2487811 A1 CA 2487811A1 CA 002487811 A CA002487811 A CA 002487811A CA 2487811 A CA2487811 A CA 2487811A CA 2487811 A1 CA2487811 A1 CA 2487811A1
- Authority
- CA
- Canada
- Prior art keywords
- virus
- cells
- use according
- nucleus
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 237
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 116
- 238000011282 treatment Methods 0.000 title claims description 33
- 230000003362 replicative effect Effects 0.000 title description 9
- 230000001419 dependent effect Effects 0.000 title description 6
- 241000700605 Viruses Species 0.000 claims abstract description 155
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 126
- 230000010076 replication Effects 0.000 claims abstract description 125
- 108700020796 Oncogene Proteins 0.000 claims abstract description 67
- 102000043276 Oncogene Human genes 0.000 claims abstract description 63
- 239000003814 drug Substances 0.000 claims abstract description 43
- 108010049024 Viral Oncogene Proteins Proteins 0.000 claims abstract description 33
- 108700005077 Viral Genes Proteins 0.000 claims abstract description 29
- 239000000824 cytostatic agent Substances 0.000 claims abstract description 25
- 238000004519 manufacturing process Methods 0.000 claims abstract description 22
- 230000002950 deficient Effects 0.000 claims abstract description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 109
- 102000039446 nucleic acids Human genes 0.000 claims description 95
- 108020004707 nucleic acids Proteins 0.000 claims description 95
- 230000037430 deletion Effects 0.000 claims description 72
- 238000012217 deletion Methods 0.000 claims description 72
- 239000013598 vector Substances 0.000 claims description 63
- 102000004169 proteins and genes Human genes 0.000 claims description 50
- 230000027455 binding Effects 0.000 claims description 36
- 108700019146 Transgenes Proteins 0.000 claims description 33
- 230000003612 virological effect Effects 0.000 claims description 28
- 230000004913 activation Effects 0.000 claims description 24
- 230000001085 cytostatic effect Effects 0.000 claims description 24
- 230000022131 cell cycle Effects 0.000 claims description 23
- 108020004459 Small interfering RNA Proteins 0.000 claims description 19
- 230000015572 biosynthetic process Effects 0.000 claims description 19
- 230000029812 viral genome replication Effects 0.000 claims description 16
- 108091023037 Aptamer Proteins 0.000 claims description 15
- 108091008819 oncoproteins Proteins 0.000 claims description 15
- 230000035772 mutation Effects 0.000 claims description 14
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 12
- 238000013518 transcription Methods 0.000 claims description 12
- 230000035897 transcription Effects 0.000 claims description 12
- 206010020843 Hyperthermia Diseases 0.000 claims description 10
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 10
- 230000036031 hyperthermia Effects 0.000 claims description 10
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 230000006698 induction Effects 0.000 claims description 8
- 102000053642 Catalytic RNA Human genes 0.000 claims description 7
- 108090000994 Catalytic RNA Proteins 0.000 claims description 7
- 108091023040 Transcription factor Proteins 0.000 claims description 7
- 102000040945 Transcription factor Human genes 0.000 claims description 7
- 230000000692 anti-sense effect Effects 0.000 claims description 7
- 239000003102 growth factor Substances 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 108091092562 ribozyme Proteins 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 6
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 238000013519 translation Methods 0.000 claims description 6
- 230000006820 DNA synthesis Effects 0.000 claims description 5
- 102000005741 Metalloproteases Human genes 0.000 claims description 5
- 108010006035 Metalloproteases Proteins 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims description 5
- 230000002018 overexpression Effects 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 102000011724 DNA Repair Enzymes Human genes 0.000 claims description 4
- 108010076525 DNA Repair Enzymes Proteins 0.000 claims description 4
- 102000001938 Plasminogen Activators Human genes 0.000 claims description 4
- 108010001014 Plasminogen Activators Proteins 0.000 claims description 4
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 4
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 4
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 4
- 230000006909 anti-apoptosis Effects 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940127126 plasminogen activator Drugs 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229960005356 urokinase Drugs 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 3
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims description 2
- 238000012512 characterization method Methods 0.000 claims description 2
- 230000001960 triggered effect Effects 0.000 claims description 2
- 108010063312 Metalloproteins Proteins 0.000 claims 1
- 102000010750 Metalloproteins Human genes 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 208000034615 apoptosis-related disease Diseases 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 230000030648 nucleus localization Effects 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 251
- 108010048626 Y-Box-Binding Protein 1 Proteins 0.000 description 224
- 102100022224 Y-box-binding protein 1 Human genes 0.000 description 221
- 210000004940 nucleus Anatomy 0.000 description 117
- 101150045895 Apela gene Proteins 0.000 description 72
- 230000014509 gene expression Effects 0.000 description 48
- 208000015181 infectious disease Diseases 0.000 description 44
- 230000001413 cellular effect Effects 0.000 description 29
- 210000004881 tumor cell Anatomy 0.000 description 26
- 230000009089 cytolysis Effects 0.000 description 25
- 125000003275 alpha amino acid group Chemical group 0.000 description 24
- 230000004807 localization Effects 0.000 description 21
- 239000002245 particle Substances 0.000 description 19
- 238000000034 method Methods 0.000 description 17
- 239000004055 small Interfering RNA Substances 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 101710114676 E1B 55 kDa protein Proteins 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 12
- 230000002074 deregulated effect Effects 0.000 description 12
- 238000013461 design Methods 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 238000001415 gene therapy Methods 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 150000001413 amino acids Chemical group 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 102100038042 Retinoblastoma-associated protein Human genes 0.000 description 10
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 238000003235 crystal violet staining Methods 0.000 description 9
- 229960000975 daunorubicin Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000036457 multidrug resistance Effects 0.000 description 9
- 230000005855 radiation Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 108050002653 Retinoblastoma protein Proteins 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000009261 transgenic effect Effects 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102100039120 Retinoblastoma-like protein 1 Human genes 0.000 description 6
- 108050002592 Retinoblastoma-like protein 1 Proteins 0.000 description 6
- 108010017842 Telomerase Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 206010048723 Multiple-drug resistance Diseases 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 210000003855 cell nucleus Anatomy 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 230000002476 tumorcidal effect Effects 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 108010093502 E2F Transcription Factors Proteins 0.000 description 4
- 102000001388 E2F Transcription Factors Human genes 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 102000048850 Neoplasm Genes Human genes 0.000 description 4
- 108700019961 Neoplasm Genes Proteins 0.000 description 4
- 230000018199 S phase Effects 0.000 description 4
- 108010006025 bovine growth hormone Proteins 0.000 description 4
- 201000010989 colorectal carcinoma Diseases 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 3
- 241001135569 Human adenovirus 5 Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 3
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000009149 molecular binding Effects 0.000 description 3
- 210000004882 non-tumor cell Anatomy 0.000 description 3
- 230000025308 nuclear transport Effects 0.000 description 3
- 230000000174 oncolytic effect Effects 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 210000003474 viral inclusion body Anatomy 0.000 description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 102000043966 ABC-type transporter activity proteins Human genes 0.000 description 2
- -1 CSF Proteins 0.000 description 2
- 102100035932 Cocaine- and amphetamine-regulated transcript protein Human genes 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000715592 Homo sapiens Cocaine- and amphetamine-regulated transcript protein Proteins 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 2
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 2
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 2
- 102100022828 Retinoblastoma-like protein 2 Human genes 0.000 description 2
- 108050002651 Retinoblastoma-like protein 2 Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 102100038313 Transcription factor E2-alpha Human genes 0.000 description 2
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 2
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 229940046836 anti-estrogen Drugs 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000001668 nucleic acid synthesis Methods 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 101710197337 Adenovirus death protein Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 101710094856 Apoptin Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 102400000059 Arg-vasopressin Human genes 0.000 description 1
- 101800001144 Arg-vasopressin Proteins 0.000 description 1
- 108091012583 BCL2 Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 101100506443 Danio rerio helt gene Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- GUGHGUXZJWAIAS-QQYBVWGSSA-N Daunorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GUGHGUXZJWAIAS-QQYBVWGSSA-N 0.000 description 1
- 102100035784 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 101710201734 E3 protein Proteins 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 241000084490 Esenbeckia delta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000018802 High Mobility Group Proteins Human genes 0.000 description 1
- 108010052512 High Mobility Group Proteins Proteins 0.000 description 1
- 101000956263 Homo sapiens Uncharacterized protein C19orf48 Proteins 0.000 description 1
- 101150083678 IL2 gene Proteins 0.000 description 1
- 101150101999 IL6 gene Proteins 0.000 description 1
- 101710125507 Integrase/recombinase Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100506445 Mus musculus Helt gene Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000033147 Parenteral nutrition-associated cholestasis Diseases 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 101000637010 Physarum polycephalum Terpene synthase 3 Proteins 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102100028588 Protein ZNRD2 Human genes 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000005406 Tissue Inhibitor of Metalloproteinase-3 Human genes 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 1
- 102100038573 Uncharacterized protein C19orf48 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- VGRSISYREBBIAL-UHFFFAOYSA-N doronine Natural products O1C(=O)C(C(Cl)C)(O)CC(C)C(C)(OC(C)=O)C(=O)OCC2=CCN(C)CCC1C2=O VGRSISYREBBIAL-UHFFFAOYSA-N 0.000 description 1
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 102000003898 interleukin-24 Human genes 0.000 description 1
- 108090000237 interleukin-24 Proteins 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 101150062876 mrp gene Proteins 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 238000001216 nucleic acid method Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical class [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000008960 regulation of mRNA stability Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 108091000036 uracil phosphoribosyltransferase Proteins 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000007482 viral spreading Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10223534.1 | 2002-05-27 | ||
| DE2002123534 DE10223534A1 (de) | 2002-05-27 | 2002-05-27 | Verwendung von Adenoviren und dafür codierenden Nukleinsäuren |
| DE10225400.1 | 2002-06-07 | ||
| DE10225400 | 2002-06-07 | ||
| DE10248039 | 2002-10-15 | ||
| DE10248039.7 | 2002-10-15 | ||
| DE10322530.7 | 2003-05-19 | ||
| DE10322530 | 2003-05-19 | ||
| PCT/EP2003/005583 WO2003099859A2 (de) | 2002-05-27 | 2003-05-27 | Neue verwendung von adenoviren und dafür codierenden nukleinsäuren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2487811A1 true CA2487811A1 (en) | 2003-12-04 |
Family
ID=29587746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002487811A Abandoned CA2487811A1 (en) | 2002-05-27 | 2003-05-27 | Use of adenoviruses replicating in a yb-1 dependent manner for the treatment of tumors |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US20060099178A1 (https=) |
| EP (1) | EP1506021B1 (https=) |
| JP (3) | JP5213298B2 (https=) |
| KR (1) | KR101083450B1 (https=) |
| CN (2) | CN101843641B (https=) |
| AU (2) | AU2003242585A1 (https=) |
| CA (1) | CA2487811A1 (https=) |
| WO (1) | WO2003099859A2 (https=) |
| ZA (1) | ZA200409361B (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10155930B2 (en) | 2002-05-27 | 2018-12-18 | Per Sonne Holm | Use of adenovirus and nucleic acids coding therefor |
| US10300096B2 (en) | 2003-11-14 | 2019-05-28 | Per Sonne Holm | Use of adenoviruses and nucleic acids that code for said viruses |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1689446B1 (de) * | 2003-11-14 | 2015-01-07 | Per Sonne Holm | Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung |
| US8361976B2 (en) | 2004-07-09 | 2013-01-29 | University Of Massachusetts | Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules |
| US20090232800A1 (en) * | 2004-12-31 | 2009-09-17 | Per Sonne Holm | E1-minus adenoviruses and use thereof |
| SG158133A1 (en) | 2004-12-31 | 2010-01-29 | Sonne Holm | Method for reversing multiple resistance in animal cells |
| WO2012022496A2 (en) | 2010-08-19 | 2012-02-23 | Per Sonne Holm | Method for killing tumor stem cells |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| KR102608590B1 (ko) | 2014-09-24 | 2023-12-01 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| WO2017147269A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
| KR20210031852A (ko) | 2018-03-05 | 2021-03-23 | 클리니쿰 레히츠 데어 이자르 데어 테크니쉔 우니베르지테트 뮌헨 | 종양 세포 붕괴성 아데노바이러스와 cdk4/6 억제제의 조합물에 의한 종양의 치료 |
| CN112292449A (zh) | 2018-04-09 | 2021-01-29 | 萨克生物研究学院 | 具有增强的复制特性的溶瘤腺病毒组合物 |
| AU2019294294A1 (en) | 2018-06-25 | 2021-02-11 | Fondazione Telethon Ets | Gene therapy |
| KR20220079551A (ko) | 2019-09-05 | 2022-06-13 | 클리니쿰 레히츠 데어 이자르 데어 테크니쉔 우니베르지테트 뮌헨 | 종양 세포 붕괴성 아데노바이러스, cdk4/6 억제제 및 추가의 치료 활성제의 조합물에 의한 종양의 치료 |
| CN120060368A (zh) * | 2020-03-23 | 2025-05-30 | 株式会社库利金 | 包含双特异性核酸分子的溶瘤病毒的结构 |
| CN114540349B (zh) * | 2020-11-27 | 2024-11-22 | 中国科学院分子细胞科学卓越创新中心 | 结合yb-1蛋白的核酸分子 |
| CA3233100A1 (en) | 2021-09-23 | 2023-03-30 | Sagittarius Bio, Inc. | Adenoviruses and methods for using adenoviruses |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US931830A (en) * | 1907-09-17 | 1909-08-24 | Harry Zimmerman | Material-cutter. |
| US4947842A (en) | 1988-09-22 | 1990-08-14 | Medical Engineering And Development Institute, Inc. | Method and apparatus for treating tissue with first and second modalities |
| ES2259800T3 (es) | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| ATE178490T1 (de) * | 1993-02-16 | 1999-04-15 | Onyx Pharmaceuticals | Cytopathische viren zur therapie und prophylaxe der neoplasie |
| US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
| ATE336587T1 (de) | 1994-06-10 | 2006-09-15 | Genvec Inc | Adenoviren-vektor systeme und zelllinien |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US6326356B1 (en) * | 1996-10-18 | 2001-12-04 | Board Of Regents, The University Of Texas System | Suppression of neu overexpression using a mini-E1A gene |
| US5707618A (en) | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
| JP3827163B2 (ja) | 1995-03-24 | 2006-09-27 | ジェンザイム・コーポレーション | 遺伝子治療用のアデノウイルスベクター |
| US6676935B2 (en) | 1995-06-27 | 2004-01-13 | Cell Genesys, Inc. | Tissue specific adenoviral vectors |
| AU7674896A (en) | 1995-10-31 | 1997-05-22 | Board Of Regents, The University Of Texas System | Adenovirus-antisense k-ras expression vectors and their application in cancer therapy |
| US6022863A (en) | 1996-05-21 | 2000-02-08 | Yale University | Regulation of gene expression |
| US6730662B1 (en) * | 1996-07-05 | 2004-05-04 | Mcgill University | Adenovirus E4 proteins for inducing cell death |
| DE69725882T2 (de) | 1996-07-05 | 2004-07-29 | Branton, Philip E., St. Lambert | Adenovirus e4 proteine für induktion von zelltod |
| DE59708838D1 (de) | 1996-08-30 | 2003-01-09 | Jens Peter Fuerste | Spiegelselektion und spiegelevolution von nucleinsäuren |
| US5994132A (en) | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
| US6110744A (en) | 1996-11-13 | 2000-08-29 | Board Of Regents, The University Of Texas System | Diminishing viral gene expression by promoter replacement |
| US6080578A (en) | 1996-12-31 | 2000-06-27 | Onyx Pharmaceuticals, Inc. | Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia |
| US6100086A (en) | 1997-04-14 | 2000-08-08 | Genzyme Corporation | Transgene expression systems |
| DE69838584T2 (de) | 1997-08-04 | 2008-06-26 | Cell Genesys, Inc., Foster City | Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| CN101618049A (zh) | 1997-10-09 | 2010-01-06 | 威尔斯塔特生物公司 | 使用病毒来治疗赘生物 |
| CN1110553C (zh) * | 1998-07-15 | 2003-06-04 | 杭州赛狮生物技术开发有限公司 | 基因工程腺病毒及其用途 |
| AU1092500A (en) | 1998-10-15 | 2000-05-01 | Canji, Inc. | Recombinant e1a deleted adenoviral vectors |
| US6649158B1 (en) | 1998-10-15 | 2003-11-18 | Canji, Inc. | Methods and compositions to induce antitumor response |
| DE19860602A1 (de) | 1998-12-29 | 2000-07-06 | Max Delbrueck Centrum | Gentransfervektor für die Diagnostik und die Therapie von malignen Tumoren |
| US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| GB9906815D0 (en) | 1999-03-24 | 1999-05-19 | Isrec | Anti-neoplastic viral agents |
| DE19929569A1 (de) | 1999-06-21 | 2000-12-28 | Holm Per Sonne | Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1 |
| AU6425800A (en) | 1999-06-30 | 2001-01-22 | Max-Delbruck-Centrum Fur Molekulare Medizin | Agents for the diagnosis, prognosis and treatment of malignant diseases |
| US6955808B2 (en) | 1999-09-24 | 2005-10-18 | Uab Research Foundation | Capsid-modified recombinant adenovirus and methods of use |
| AU1087701A (en) | 1999-10-15 | 2001-04-30 | Canji, Inc. | Targeted vectors |
| US6140126A (en) | 1999-10-26 | 2000-10-31 | Isis Pharmaceuticals Inc. | Antisense modulation of Y-box binding protein 1 expression |
| CN1382218A (zh) * | 1999-11-15 | 2002-11-27 | 昂尼克斯药物公司 | 溶瘤腺病毒 |
| DE10015413A1 (de) | 2000-03-23 | 2001-09-27 | Max Delbrueck Centrum | Mittel zur Diagnose und Therapie viraler Erkrankungen |
| WO2001092549A2 (en) | 2000-05-31 | 2001-12-06 | Genvec, Inc. | Method and composition for targeting an adenoviral vector |
| AU784975B2 (en) | 2000-10-11 | 2006-08-10 | Sumitomo Chemical Company, Limited | DNA-binding protein YB-1-containing collagen accumulation inhibitors |
| AU2002235141A1 (en) | 2000-11-27 | 2002-06-03 | Geron Corporation | Glycosyltransferase vectors for treating cancer |
| US20030095989A1 (en) | 2000-12-18 | 2003-05-22 | Irving John M. | Chimeric cytolytic viruses for cancer treatment |
| DE10150945A1 (de) | 2001-10-16 | 2003-04-17 | Holm Per Sonne | Adenovirale Systeme und deren Anwendungen |
| EP1346058B1 (de) | 2000-12-28 | 2007-05-02 | Per Sonne Holm | Adenovirale systeme und deren anwendungen |
| US20030138405A1 (en) | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| WO2003025190A1 (en) | 2001-09-14 | 2003-03-27 | The New Industry Research Organization | Tumor-specific promoter and use thereof |
| DE10150984A1 (de) | 2001-10-16 | 2003-04-17 | Holm Per Sonne | Verwendung des adenoviralen E2-late-Promotors |
| EP1497440B1 (en) | 2002-04-25 | 2008-08-20 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
| JP5213298B2 (ja) * | 2002-05-27 | 2013-06-19 | ホルム，ペル・ゾンネ | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
| MXPA05004074A (es) | 2002-10-15 | 2005-09-20 | Sonne Holm Per | Nuevos adenovirus, acidos nucleicos que los codifican y su uso. |
| US20050042217A1 (en) | 2003-03-19 | 2005-02-24 | Yan Qi | Specific inhibition of allorejection |
| EP1689446B1 (de) | 2003-11-14 | 2015-01-07 | Per Sonne Holm | Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung |
| CA2546178A1 (en) | 2003-11-14 | 2005-06-09 | Per Sonne Holm | New use of adenovirus and nucleic acids coding therefor |
| US7851218B2 (en) | 2004-12-13 | 2010-12-14 | Schering Corporation | Cell lines for production of replication-defective adenovirus |
| US20090232800A1 (en) | 2004-12-31 | 2009-09-17 | Per Sonne Holm | E1-minus adenoviruses and use thereof |
| SG158133A1 (en) | 2004-12-31 | 2010-01-29 | Sonne Holm | Method for reversing multiple resistance in animal cells |
| WO2007103825A2 (en) | 2006-03-02 | 2007-09-13 | The Board Of Regents Of The University Of Texas System | Combination therapy with oncolytic adenovirus |
-
2003
- 2003-05-27 JP JP2004508113A patent/JP5213298B2/ja not_active Expired - Lifetime
- 2003-05-27 AU AU2003242585A patent/AU2003242585A1/en not_active Abandoned
- 2003-05-27 CN CN201010161559.4A patent/CN101843641B/zh not_active Expired - Fee Related
- 2003-05-27 US US10/515,238 patent/US20060099178A1/en not_active Abandoned
- 2003-05-27 KR KR1020047019231A patent/KR101083450B1/ko not_active Expired - Fee Related
- 2003-05-27 CA CA002487811A patent/CA2487811A1/en not_active Abandoned
- 2003-05-27 WO PCT/EP2003/005583 patent/WO2003099859A2/de not_active Ceased
- 2003-05-27 EP EP03755145.4A patent/EP1506021B1/de not_active Expired - Lifetime
- 2003-05-27 CN CN03812310XA patent/CN1655827B/zh not_active Expired - Fee Related
-
2004
- 2004-11-22 ZA ZA2004/09361A patent/ZA200409361B/en unknown
-
2010
- 2010-04-28 US US12/769,435 patent/US10155930B2/en not_active Expired - Lifetime
- 2010-09-09 AU AU2010219364A patent/AU2010219364B2/en not_active Ceased
-
2012
- 2012-05-22 JP JP2012116438A patent/JP5719800B2/ja not_active Expired - Lifetime
-
2014
- 2014-08-04 JP JP2014158673A patent/JP2014224141A/ja not_active Withdrawn
-
2017
- 2017-03-07 US US15/452,470 patent/US10538744B2/en not_active Expired - Fee Related
-
2018
- 2018-10-31 US US16/176,461 patent/US10731136B2/en not_active Expired - Fee Related
-
2019
- 2019-12-05 US US16/704,669 patent/US11268073B2/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10155930B2 (en) | 2002-05-27 | 2018-12-18 | Per Sonne Holm | Use of adenovirus and nucleic acids coding therefor |
| US10538744B2 (en) | 2002-05-27 | 2020-01-21 | Per Sonne Holm | Use of adenovirus and nucleic acids coding therefor |
| US10731136B2 (en) | 2002-05-27 | 2020-08-04 | Per Sonne Holm | Use of adenovirus and nucleic acids coding therefor |
| US11268073B2 (en) | 2002-05-27 | 2022-03-08 | Per Sonne Holm | Use of adenovirus and nucleic acids coding therefor |
| US10300096B2 (en) | 2003-11-14 | 2019-05-28 | Per Sonne Holm | Use of adenoviruses and nucleic acids that code for said viruses |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101843641A (zh) | 2010-09-29 |
| US10731136B2 (en) | 2020-08-04 |
| CN1655827B (zh) | 2010-06-23 |
| US10155930B2 (en) | 2018-12-18 |
| US20190055522A1 (en) | 2019-02-21 |
| WO2003099859A2 (de) | 2003-12-04 |
| JP2012179058A (ja) | 2012-09-20 |
| AU2010219364A1 (en) | 2010-09-30 |
| US10538744B2 (en) | 2020-01-21 |
| AU2003242585A2 (en) | 2003-12-12 |
| JP5213298B2 (ja) | 2013-06-19 |
| JP2014224141A (ja) | 2014-12-04 |
| US20110033424A1 (en) | 2011-02-10 |
| US20060099178A1 (en) | 2006-05-11 |
| JP5719800B2 (ja) | 2015-05-20 |
| CN1655827A (zh) | 2005-08-17 |
| US11268073B2 (en) | 2022-03-08 |
| US20180002674A1 (en) | 2018-01-04 |
| EP1506021B1 (de) | 2019-05-01 |
| CN101843641B (zh) | 2014-09-17 |
| KR101083450B1 (ko) | 2011-11-16 |
| ZA200409361B (en) | 2005-08-31 |
| EP1506021A2 (de) | 2005-02-16 |
| WO2003099859A3 (de) | 2004-04-15 |
| JP2006512284A (ja) | 2006-04-13 |
| AU2003242585A1 (en) | 2003-12-12 |
| KR20050008744A (ko) | 2005-01-21 |
| US20200095560A1 (en) | 2020-03-26 |
| AU2010219364B2 (en) | 2011-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11268073B2 (en) | Use of adenovirus and nucleic acids coding therefor | |
| US10300096B2 (en) | Use of adenoviruses and nucleic acids that code for said viruses | |
| AU2010257327B2 (en) | Adenovirus expressing genes in reverse order and use thereof | |
| CA2590257A1 (en) | Novel adenoviruses, nucleic acids that code for the same and the use of said viruses | |
| RU2393221C2 (ru) | Аденовирус с обращенной генной экспрессией и его применение | |
| AU2015201828B2 (en) | Novel use of adenoviruses and nucleic acids coding therefor | |
| CN1705740B (zh) | 具有反向基因表达的腺病毒及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20201007 |